Guidelines

First-ever best practices for percutaneous axillary access


 

FROM THE JOURNAL OF THE SOCIETY FOR CARDIOVASCULAR ANGIOGRAPHY AND INTERVENTIONS

The Society for Cardiovascular Angiography and Interventions (SCAI) has issued the first statement on best practices for percutaneous axillary arterial access and training.

The position statement helps fill a gap amid increasing use of transaxillary access as an alternative to the femoral route for large-bore transcatheter aortic valve replacement (TAVR), endovascular aortic repair (EVAR), and mechanical circulatory support.

“The need for alternative access has increased as we are using more and more TAVR for our elderly population, and EVAR has also increased,” writing committee chair Arnold H. Seto, MD, Long Beach VA Health Care System (California) said in an interview. “There’s also a set of patients who require balloon pumps for a prolonged period, and people were using balloon pumps from the axillary approach, which were not custom-designed for that purpose.”

He noted that the evidence base leans heavily on case reports and case series, and that they were approached for guidance by a vendor developing a balloon pump specific to axillary access. “So that helped spur all of us to get together and decide to write up something on this topic, which was developing, but was certainly picking up steam rapidly.”

The statement was published in the Journal of the Society for Cardiovascular Angiography and Interventions, and it reflects the consensus of experts in heart failure, interventional cardiology and radiology, and cardiothoracic and vascular surgery. It reviews anatomic considerations and risks for percutaneous axillary access and suggests techniques for insertion, closure, and complication management.

Although the femoral artery is the most frequent access site for percutaneous large-bore procedures, the document notes that this approach may be limited in 13%-20% of patients because of prior surgeries or severe aortoiliac and/or iliofemoral atherosclerotic disease, tortuosity, or calcification.

“Absolutely, the femoral should be the predominant access site,” Dr. Seto said. Whenever there is a compromised femoral artery, “the axillary artery, which is rarely involved with atherosclerosis, makes for the most optimal alternative access. Other forms of alternative access, including transcaval and transcarotid, are possible but have their own issues and difficulties.”

Axillary access has traditionally been done through an open surgical approach, which allows for direct puncture, primary arterial repair, or placement of a sidearm conduit. Percutaneous transaxillary access avoids a surgical incision and general anesthesia and, theoretically, reduces the risk of infection, he said. It also allows for better mobility for patients, for example, who may have a balloon pump in place for weeks or even a month when waiting for a bridge to transplant.

In terms of technique, key recommendations include:

  • Gaining access preferably through the left axillary
  • Inserting the needle directly through the pectoralis minor into the second segment of the axillary artery
  • Using a shallow-needle angle of 25-30 degrees to improve access success and decrease sheath malformation, kinking, bleeding, or vessel perforation
  • Using micropuncture needles to minimize trauma to adjacent tissues
  • Abducting the patient’s arm to 45-90 degrees to reduce tortuosity
  • Using angiographic and ultrasound techniques to optimize vascular access

Pages

Recommended Reading

Extraction of infected implanted cardiac devices rare, despite guidelines
MDedge Cardiology
Surgeons in China ‘are the executioners,’ procuring organs before brain death
MDedge Cardiology
Renal denervation BP benefits remain at 3 years: SPYRAL HTN-ON
MDedge Cardiology
TAVI device shows less deterioration than surgery 5 years out
MDedge Cardiology
Empagliflozin rapidly improves acute heart failure symptoms in hospitalized patients
MDedge Cardiology
FFR not better, just different from IVUS for revascularizing intermediate stenoses
MDedge Cardiology
Icosapent ethyl’s CV mortality benefit magnified in patients with prior MI
MDedge Cardiology
Will you have cardiac arrest? New tech may predict if and when
MDedge Cardiology
FDA warns of pump defect with Medtronic HVAD system
MDedge Cardiology
FDA clears mavacamten (Camzyos) for obstructive hypertrophic cardiomyopathy
MDedge Cardiology